Philadelphia chromosome (Ph)-positive acute lymphocytic leua novel c-abl protein of 190 kDa was detected; [4] [5] [6] diagnosis, 13 and some of these patients have the translocation.
ABL exon 1B and exon II (a2). 7 The bcr breakpoint, in coning to ECL-WB. Eight had p190 disease, and one had p210 disease. Among the 16 patients with IM, none demonstrated the trast, is distinct between p210 and p190. P210 has two iso- Patients' characteristics are shown in Table 1 . Nine (22%) of the 41 ALL patients showed Ph-positive cells by cytogenetic specimens, and could detect both p210 and p190 oncoproteins even in some patients lacking the Ph chromosome at the analysis ( Table 1) . Five of the nine had CALLA-positive disease, and all nine were positive for the BCR-ABL oncoprotein time of diagnosis. 19, 20 In this study, we describe the application of ECL-WB in detecting the Ph-related proteins in the by ECL-WB analysis ( Figure 1 and Table 2 ). Eight of nine demonstrated p190 and one had p210. Following induction therperipheral blood from patients with Ph-positive ALL.
apy with HYPER-CVAD, eight of the nine ( The characteristics of the nine patients with ECL-WB postive results for BCR-ABL at the time of diagnosis as well as two Patients underwent routine workup at presentation. This included a history and physical examination; a complete additional patients with ECL-WB done only at follow-up are presented in Table 2 . blood count, with differential and platelet counts; SMA12, including the determination of hepatic and renal functions; bone marrow studies for morphology, cytochemical and enzymatic stains, immunophenotyping, karyotypic analysis, and Follow-up studies electron microscopy; and peripheral blood analysis through ECL-WB as described below. Cytogenetic studies included a A total of seven patients had follow-up ECL-WB analysis from peripheral blood while in CR at 11 to 30 weeks after diagnosis complete karyotypic analysis involving at least 25 metaphases when available, as previously described. 21 as shown in Table 2 and Figure 1 . BCR-ABL/ABL ratios at follow-up ranged between 0 and 0.06. Patients 1 and 4 had The diagnosis of acute leukemia was based on the FrenchAmerican-British (FAB) criteria and on histochemical stains. 22 detectable protein 11 and 30 weeks post-diagnosis. Both patients relapsed at 31 and 42 weeks, respectively. On the ALL was diagnosed if the blasts were morphologically lymphoid, myeloperoxidase negative, and terminal deoxyother hand, patients 5, 6 and 9, all being initially positive, had no detectable BCR-ABL protein at 6, 25 and 24 weeks of folnucleotidyl transferase (TdT) positive and/or common acute lymphocytic leukemia antigen (CALLA) positive.
low-up. Patients 5 and 6 remain in CR at 36+ and 55+ weeks, while patient 9 relapsed at 35 weeks. However, patient 9 had Patients with ALL received intensive sequential induction therapy with the HYPER-CVAD program as previously a ratio of only 0.6 at diagnosis (compared with more than 2.5 for patients 5 and 6) and thus was not expected to have a described. 23 Response criteria were as previously reported. 24 Complete detectable BCR-ABL band while in remission. Patients F1 and remission (CR) was defined as a morphologically normal marrow with Ͻ5% blasts, and normal peripheral blood counts with Ͼ10 3 granulocytes/l and Ͼ10 5 platelets/l. Remission F2, who were not analyzed at diagnosis, both had p210 by row metaphases) and both relapsed 12 and 4 weeks after the follow-up studies, respectively (patients 4 and F1 in Table 2 ). ECL-WB.
Concurrent cytogenetic analysis at the time of follow-up is A third patient with detectable protein at follow-up had one Ph metaphase out of 20 and relapsed 20 weeks after follow-up also shown in Table 2 . Among the four patients with detectable protein by ECL-WB at follow-up (patients 1, 4, F1 and studies. The fourth patient with detectable protein at follow-up (patient F2 in Table 2 ) had IM (one of two metaphases Ph+) F2), two were diploid (one with 100% allogeneic bone mar-by cytogenetic analysis and remains in CCR at 79+ weeks intensity as revealed by densitometry was high (у1.4) except for one patient with a ratio of 0.6. This ratio was previously from diagnosis.
shown to correlate with the percent of Ph metaphases in CML patients. 20 That relationship was not linear although it was for the in vitro studies mentioned above. Such correlation Patients with insufficient metaphases (IM) by cytogenetic studies between the percent of Ph-positive metaphases and band intensity ratios may not be as clinically relevant in ALL as it is in CML, in which the percentage of Ph-positive metaphases Although none of the patients with IM demonstrated the oncoprotein at the time of diagnosis, one did demonstrate the prois used in the long-term monitoring of therapy. Our results showed a concordance rate of 100% with cytogenetics. While tein at trace levels (0.02) at the time of follow-up (Table 2) . Previous studies of six CML patients with 0% Ph metaphases we did not detect BCR-ABL protein-positive ALL in patients with insufficient metaphases or diploid karyotype, this finding did demonstrate the BCR-ABL protein. 20 These findings suggest that this technique, while clearly less sensitive than polymay be due to the small sample of the study group, and should be seen when more patients are studied, as was shown for merase chain reaction (PCR), may detect clinically significant clonal cells in PB in patients with IM or negative cytogenetics.
other methods of detection of Ph-positive ALL. 13, 15 It is of interest that in our study the incidence of p190 (8/11Ph-posiIn contrast, analyses of more than 95 samples from patients with various other medical problems have not yet detected a tive ALL) was higher than in a previous study using PCR for BCR-ABL mRNA, 25 and that none of 16 patients with insuffalse positive result. Similarly, analyses of none of the 231 samples from patients with Ph-positive CML (with predomificient metaphases expressed Ph-related protein abnormalities. This may be due to differences in study groups and small nant Ph-positive cells) detected a false negative result.
numbers of patients. It is also possible that the p210 abnormality may not express itself at the protein level as frequently as does the p190 abnormality; or it may be less detectable at Concurrent Southern blot analysis the protein level in patients with IM. To clarify these discrepancies, we reviewed Southern blot analysis for the BCR Southern blot analysis to detect b2a2 or b3a2 breakpoints that generate the p210 protein was carried out at the time of diagrearrangement in patients with IM. In no patient was rearrangement of the BCR gene for the p210 breakpoints nosis on 40 of the 41 ALL patients; one patient had insufficient specimen. All 40 patients, including all eight Ph-positive detected. For the one patient in whom the p210 protein was detected by Western blot analysis at diagnosis, the available patients expressing p190, and the 16 patients with IM and no detected oncoprotein, had germline pattern on Southern blot specimen was insufficient to conduct the Southern blot analysis. Thus, for the number of patients tested, the concordance analysis. The only patient to have demonstrated p210 by ECL-WB could not be analyzed because of insufficient sample.
rate between the Southern and Western blots for negative detection of the p210 abnormality was 100%. These findings, together with those from other studies indicate that specimens should be analysed from more patients in whom all markers Discussion of Ph abnormality -cytogenetics, hypermetaphase fluorescent in situ hybridization or FISH, 27 PCR for BCR-ABL mRNA 28, 29 Philadelphia-positive ALL is associated with poor prognosis. CR is achieved in only 50-70% of patients with conventional and Western blot -are done simultaneously. Such an approach would facilitate the clarification of some aspects of induction regimens; median patient survival is 11 months. 25 To date, only allogeneic bone marrow transplantation has the the disease biology as well as the comparison of the detection rates of different methods. potential to produce long-term relapse-free survival, 26 identification of the Ph translocation is important prognostically With follow-up studies, three of four patients who had detectable bands on Western blot in remission have relapsed and therapeutically.
This study shows ECL-WB to be reliable in detecting the compared with one of three patients with no detectable band ( Table 2 and Figure 1 ). Unlike data at the time of diagnosis, BCR-ABL oncoprotein in patients with Ph-positive ALL. It is done on peripheral blood samples, and is conveniently comfollow-up comparative data show discordance between ECL-WB and cytogenetic analysis. Two of the four patients with pleted in 2-3 days as compared to about 2 weeks for standard cytogenetics. Unlike both cytogenetics and Southern blot, it negative cytogenetic studies had a detectable band on ECL-WB, which suggests that ECL-WB could detect residual disreadily differentiates p190 and p210 ALL. It also reveals active synthesis of the oncoprotein although the prognostic impliease not detected by cytogenetic studies. In contrast, neither of two patients with no detectable band by ECL-WB had cations of this information (in CML) is not clear. The method was previously shown to detect as few as 2000-3000 K562
detectable Ph-positive metaphases by cytogenetic studies. ECL-WB may thus have the potential to predict early relapse cells in a total of 1 × 10 6 cells, with the BCR-ABL band intensity correlating with the number of cells in a linear fashion.
following induction chemotherapy or even following allogeneic bone marrow transplant. In fact, one of the four A similar linear relationship with comparable sensitivity was described in experiments conducted with 100% Ph-positive patients who relapsed had had an allogeneic bone marrow transplant; in this patient, follow-up Western blot but not cells from CML patients; BCR-ABL oncoprotein expression was detected in WBC mixtures containing as few as 0.2-0.4% cyogenetics predicted relapse ( Table 2 , patient 2). Larger numbers of patients, longer follow-up, and direct comparison with of BCR-ABL expressing leukemia cells. In addition, previous experience with this technique in CML suggested a high level RT-PCR will better characterize the sensitivity, specificity and potential role of ECL-WB in the follow-up of patients after of specificity and excellent sensitivity for patients with Phpositive metaphases of у20%. 19, 20 therapy.
In summary, new techniques are evolving that may prove In the analysis reported here, all Ph-positive ALL patients tested for the oncoprotein at the time of diagnosis had a to be superior to cytogenetics in detecting Ph-positive disease, monitoring minimal residual disease, and predicting progdetectable BCR-ABL band. The ratio of BCR-ABL/ABL band Clinical significance of the BCR-ABL fusion gene in adult acute nosis. ECL-WB is a relative quick technique which is conlymphoblastic leukemia: a Cancer and Leukemia Group B study.
veniently done on blood specimens, has a high concordance 
